CURIS INC
No enriched coverage for $CRIS in the last 7 days.
No SEC Form 4 filings for $CRIS in the last 30 days.
See all $CRIS insider activity →Curis raised $8.5M in a PIPE offering, including common stock and warrants, to fund R&D and operations until December 2026. The company also amended warrants to lower their exercise price to $0.60 and engaged placement agents for the offering. The closing is targeted for October 19, 2026.
CURIS INC (CRIS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 16, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the purchase and
Curis, Inc. (CRIS) raised $8.5M via a private placement of 16.67M shares and 16.67M warrants at $0.51 per unit, with common warrants at $0.60. Certain 2026 warrants will be repriced to $0.60. Proceeds are expected to support operations through initial CLL data in December 2026, according to the company.
Recent CRIS coverage spans corporate actions, financial news and technology.
The new financing should extend cash runway and support R&D, likely providing short‑term price support.
Equity dilution and new capital may pressure the stock price in the short term.
The dilutive financing increases share count and may weigh on the stock.
Equity dilution from a small raise may weigh on the stock.
Moderate insider sell amid overvaluation view.
AlphAI scores every news story that mentions CRIS with an AI model for sentiment and relevance, and aggregates insider trades from CURIS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Curis raised $8.5M in a PIPE offering, including common stock and warrants, to fund R&D and operations until December 2026. The company also amended warrants to lower their exercise price to $0.60 and engaged placement agents for the offering. The closing is targeted for October 19, 2026.
1 min readCURIS INC (CRIS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On October 16, 2026, Curis, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the purchase and
2 min readCuris, Inc. (CRIS) raised $8.5M via a private placement of 16.67M shares and 16.67M warrants at $0.51 per unit, with common warrants at $0.60. Certain 2026 warrants will be repriced to $0.60. Proceeds are expected to support operations through initial CLL data in December 2026, according to the company.
1 min readCuris Inc. plans an $8.5M private placement with healthcare investors, using proceeds to fund emavusertib trials through December. The biotech firm develops emavusertib for blood cancers, with Orphan Drug Designation from U.S. and EU regulators. Curis lacks sufficient cash for 12 months of operations and requires additional funding.
1 min readEnovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.
3 min readCuris, Inc. (CRIS) priced a public offering with certain healthcare-focused institutional investors for 3.733 million shares or pre-funded warrants plus warrants. Combined price is $1.50 per share, with expected gross proceeds of about $5.6 million, closing around Aug. 14, 2026. Warrants exercise at $1.75, pre-funded warrants at $0.01. CRIS focuses on Emavusertib (CA-4948).
2 min readCuris (NASDAQ:CRIS) reported progress in clinical programs for its oral IRAK4 and FLT3 inhibitor targeting blood cancers. HC Wainwright said TakeAim CLL enrollment is ahead of plan, with year-end guidance raised to 5-10 patients, and reiterated a Buy rating while lifting its price target from $17 to $43. The note also updated emavusertib valuation assumptions and shifted PCNSL launch to 2029 and AML/MDS to 2032.
5 min readCuris Inc. (NASDAQ:CRIS) reported updated clinical results for emavusertib and expanded trial timeline guidance. In its TakeAim Primary CNS Lymphoma study, overall response was 100% (5/5) in BTK-naive evaluable patients and 86% (6/7) overall. BTK-experienced response was 26% (10/39). In TakeAim CLL, Curis added sites and raised its year-end data target to 5-10 patients in Dec 2026.
4 min readCuris, Inc. (NASDAQ:CRIS) shares rose about 11% after the company reported updated emavusertib clinical data in primary CNS lymphoma and raised enrollment guidance for its chronic lymphocytic leukemia study. In PCNSL, it cited an 86% overall response rate in BTK inhibitor-naïve and 26% in BTKi-experienced patients as of July 1, 2026. For CLL, it guided year-end enrollment to 5-10 patients.
4 min readCuris Inc. (NASDAQ:CRIS) shares rose 8.51% to $0.46 after hours Wednesday after the company confirmed its previously approved reverse stock split will take effect Thursday at 5:00 p.m. ET, with split-adjusted trading starting Jul. 6. Shareholders approved a 1-for-5 to 1-for-25 split to help regain Nasdaq’s $1 bid compliance.
3 min read
